Opioid Agonist Therapy 101: An Introduction to Clinical Practice

Acute, Chronic & Perioperative Pain Management in the Context of OAT

Slide development - Kulvir Badesha MD, FRCPC Nicole Nakatsu B.Sc. Pharm, BCPS, EPPh

Erin Knight, MD, CCFP(AM), ISAM

Medical Director, Addiction Services - Health Sciences Centre Co-medical Lead, RAAM hub – Shared Health Program Director, Addiction Medicine ES Program – U. Manitoba Medical Director, Island Lake Regional Addiction Program – FARHA Addiction Physician, OAT clinic, OCN – Opaskwayak Health Authority

Family Physician, Aboriginal Health and Wellness Centre

Disclosure of Commercial Support

- This program has received financial support from The College of Physicians and Surgeons of Manitoba in the form of funding for payment of presenters and organizers.
- This program has received in-kind support from The College of Physicians and Surgeons of Manitoba in the form of logistical support.

Potential for conflict(s) of interest:

None identified

Faculty/Presenter Disclosure

Faculty: Erin Knight

Relationships with commercial interests:

None

Learning Objectives

- Review definitions, pathophysiology, and classification of pain
- Understand the epidemiology and management of chronic pain
- Outline rational pharmaceutical options for pain management
- Review current guidelines for Opiate Replacement Therapy (OAT) with respect to patients with concurrent pain
- Discuss management of pain for patients on OAT with acute and chronic pain through case-based learning

Case 1: Jim

- 52 year old male
- Long standing history of alcohol use disorder
- Introduced to opioids via his wife
- Stabilized on methadone for a few years with a few minor relapses only
- No other medical history or medications

Case 1: Jim

- Jim's wife leaves for 2 weeks to visit with family
- Jim takes the opportunity to indulge in a few beer
- Unfortunately, while on a ladder, Jim falls and has an acute navicular fracture for non operative management
- He is having considerable pain, what do you do?

Case 2: Kathy

- Kathy is a 33 year old female
- She has a positive family history of substance use disorder
- She herself has a long standing history of an opioid use disorder for which she is on 28mg of buprenorphine/naloxone
- She also has known Crohn's Disease which is currently in remission
- She is transferred your clinic with the following....

Pyoderma Gangrenosum



Case 2: Kathy

- Kathy presents in crisis
- She is receiving Infliximab and prednisone and is being followed by a gastroenterologist as well as a dermatologist. She has had a poor response to therapy thus far
- She is in pain. How do you proceed?


Pain Overview

Definitions

- Nociception
 - The process by which information about a noxious stimuli is conveyed to the brain. It is the total sum of the neural activity that occurs prior to the cognitive processes that enable human to identify a sensation as pain

Pain

An unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage....it is always subjective.



Classification of Pain

- Type: nociceptive, neuropathic pain
- Temporal: acute pain, chronic pain
- Location: soft tissue, bones/joints, visceral pain

Goals of Chronic Pain Management

- Focus visits on function
- Identify complex interactions that may be driving or enhancing the pain experience
- Collaborative care models

Pain Overview

Pharmaceutical Options

Acute Nociceptive/Perioperative Pain

Strong opioids

- e.g. morphine, diamorphine, fentanyl
- Pain severity 8+/10

Mild opioids

- e.g. codeine, dihydrocodeine, co-codamol
- Pain severity 5-8/10
- Non-opioids
- e.g. paracetemol +/- NSAID
- Pain severity 2-5/10

Adapted from The World Health Organisation pain ladder¹

But what about the methadone/buprenorphine?

- Continue (and optimize) OAT
 - OAT dose is baseline for preventing withdrawal
 - Once daily dosing will not provide significant pain relief
- Split dosing may be an option for those eligible for carries
- If using opioids start with dosing similar to that used for a person not on OAT
 - Caveat: may need to be larger and/or more frequent doses, due to:
 - 1) Opioid tolerance
 - 2) More severe pain experience
- Avoid using person's previous or current drug of choice if possible
- Shared decision making is important, discussing risks, framing expectations
- Consideration of regional anaesthesia for perioperative pain

Buprenorphine hmmm...

Buprenorphine binds tightly to the mu-opioid receptor as a partial agonist

Contents lists available at ScienceDirect



Regulatory Toxicology and Pharmacology

Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtph

Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs $^{\diamond}$

Donna A. Volpe^{a,*}, Grainne A. McMahon Tobin^a, R. Daniel Mellon^b, Aspandiar G. Katki^a, Robert J. Parker^a, Thomas Colatsky^a, Timothy J. Kropp^c, S. Leigh Verbois^c

Drug	Ki (nM)	Drug	K _i (nM)	Drug	$K_{\rm I}({\rm nM})$
Tra madol	12,486	Hydrocodone	41.58	Butorphanol	0.7622
Codeine	734.2	Oxycodone	25.87	Levorphanol	0.4194
Meperidine	450.1	Diphenoxylate	12.37	Oxymorphone	0.4055
Propoxy phene	120.2	Alfentanil	7.391	Hydromorphone	0.3654
Pentazocine	117.8	Methadone	3.378	Buprenorphine	0.2157
		Nalbuphine	2.1.18	Sufentant	0.1380
		Fentanyl	1.346		
		Morphine	1.168		

Buprenorphine maintenance and *mu*-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy

Mark K. Greenwald^{a,*}, Sandra D. Comer^b, and David A. Fiellin^c




Fig. 1. Left panel: Non-linear regression curves on μ OR availability (non-displaceable binding potential, BP_{ND}) fitted to brain region-of-interest (ROI) [¹¹C]-carfentanil PET data from Greenwald et al. (2003) for different buprenorphine (BUP) maintenance doses (log2–linear plot) at 4-h post-dose. The seven ROIs illustrated are: Brodmann area (BA) 10 in prefrontal cortex (PFC); BA 25 in subgenual anterior cingulate cortex (ACC); BA 32 in rostral ACC; caudate nucleus; nucleus accumbens; thalamus; and amygdala. Dashed lines indicate estimated range of μ OR availability across ROIs for an 8-mg/day BUP dose (12–33%). See Table 1 for estimates of μ OR availability (based on these curve fits) for BUP doses that were not experimentally studied. Right panel: Non-linear regression curves on regional μ OR availability (BP_{ND}) fitted to [¹¹C]-carfentanil PET data from Greenwald et al. (2007) following discontinuation of BUP 16-mg/day maintenance. The Y-intercept values at the 4-h time point for each ROI were adjusted to data for the identical condition (4 h after BUP 16-mg) in the Greenwald et al. dose-response study (2003).

- BUP 8 mg/d- approx. 65% receptor saturation, 35% of receptors are available.
- Doses above 16 mg/d- approx 95% receptor saturation



- Continue buprenorphine
- Do NOT routinely prescribe supplemental opioids Do NOT change the buprenorphine dose
- Consider adjuncts NSAIDs, membrane stabilizers, acetaminophen, local anesthetic agents, regional anesthetic techniques



- Surgical team should contact buprenorphine providers and cont aware of surgery and have a plan to reinstitute therapy
- Assess amount of time since last dose. If the following dose/time intervals are met, treat with traditional opioids using an id-olerant dosing:

0-4 mg per day - stop x 24 h before tu

>4-8 mg per day – stop x 48 h before surgery
>8-12 mg per day – stop 3.4 h before surgery
>12 mg – requires preoperative management plan with buprenorphine provider

renorphine

- Cancel surgery Maybe better: postpone or schedule surgery such that the following requirements can be met
- Patient should return to buprenorphine provider and be placed on short-acting opioid or be weaned off before surgery. A plan for follow-up and reinstitution of therapy should be established.

0-4 mg per day – stop x 24 h before surgery >4-8 mg per day - stop x 48 h before surgery

>8-12 mg per day - stop x 72 h before surgery

Off Buprenorphine

- Anticipate patient's opioid requirements will be similar to opioid-tolerant or highly-tolerant patient
- Surgical team should ensure appropriate outpatient follow-up with buprenorphine provider
- Consider adjuncts NSAIDs, membrane stabilizers, acetaminophen, local anesthetic agents, regional anesthetic techniques

Fig. 1. Suggestions are outlined for patients presenting for elective surgeries taking buprenorphine. NSAIDs = nonsteroidal antiinflammatory drugs. #Transdermal buprenorphine need not be discontinued prior to elective surgery regardless of dose.

Anesthesiology 2017; 126:1180-6

or she is still taking bupre-

norphine and establish total

daily dose#

Ask patient if

taking buprenorphine and establish total

daily dose#

Minimal

to

No Pain

Moderate

to Severe Pain

Elective

Surgery

Preoperatively:

Surgical team should assess anticipated

postoperative pain and opioid requirements

he or she is still

g opinion

British Journal of Anaesthesia, 123 (2): e333-e342 (2019)

doi: 10.1016/j.bja.2019.03.044 Advance Access Publication Date: 29 May 2019 Special Article

Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process

Akash Goel^{1,2}, Saam Azargive^{1,3}, Joel S. Weissman^{2,4}, Harsha Shanthanna⁵, John G. Hanlon¹, Bana Samman¹, Mary Dominicis¹, Karim S. Ladha¹, Wiplove Lamba⁶, Scott Duggan³, Tania Di Renna¹, Philip Peng¹, Clinton Wong⁷, Avinash Sinha⁸, Naveen Eipe⁹, David Martell¹⁰, Howard Intrater¹¹, Peter MacDougall⁹, Kwesi Kwofie¹², Mireille St-Jean¹³, Saifee Rashiq¹⁴, Kari Van Camp¹⁵, David Flamer¹, Michael Satok-Wolman¹⁵ and Hance Clarke^{1,15,*}

¹Department of Anaesthesia, University of Toronto, Canada, ²T.H. Chan School of Public Health, Harvard University, USA, ³Department of Anaesthesia, Queen's University School of Medicine, Canada, ⁴Department of Surgery, Brigham and Women's Institute, USA, ⁵Department of Anaesthesia, McMaster University, Canada, ⁶Department of Psychiatry, University of Toronto, Canada, ⁷Department of Anaesthesia, University of British Columbia, Canada, ⁸Department of Anaesthesia, McGill University, Canada, ⁹Department of Anaesthesia, University of Ottawa, Canada, ¹⁰Department of Family Medicine, Dalhousie University, Canada, ¹¹Department of Anaesthesia, University of Manitoba, Canada, ¹²Department of Anaesthesia, Dalhousie University, Canada, ¹³Department of Family Medicine, University of Ottawa, Canada, ¹⁴Department of Anaesthesia, University of Alberta, Canada and ¹⁵Pain Research Unit, Toronto General Hospital, University of Toronto, Canada

*Corresponding author. E-mail: hance.clarke@uhn.ca

For all surgeries (elective or emergent); for all doses and formulations of SL and TD buprenorphine; for all expected post-operative pain levels; for all risk category patients (with respect to OUD and/or PD)

Preoperative planning

Maintain buprenorphine therapy at same dose until day of surgery

In-Hospital pain management

If patient experiences incomplete Analgesia on POD1:

> Initiate adjunct analgesia (NSAIDs, Acetaminophen, Gabapentin/Pregabalin, Ketamine, Dexmedetomidine, Lidocaine)

 If Inadequate analgesia persists: Initiate full mu agonist^a (Hydromorphone, Morphine, Fentanyl)

 If (1) and (2) Fail: Consider reducing buprenorphine dose^a

a. Consider moving to a monitored setting for the following 24 h if a Buprenorphine dose is reduced in the context of a full mu agonist

Discharge planning

Discharge patient on some dose of buprenorphine

If necessary, discharge patient on limited prescription of full mu agonist

PERIOPERATIVE

1. OUTPATIENT PROVIDER INVOLVEMENT 2. ENGAGEMENT OF PATIENT IN ANALGESIC CARE: SETTING AND MANAGING EXPECTATIONS 3. CONSIDERATION OF REGIONAL ANALGESIA

Fig. 3. A summary of recommendations for perioperative management of patients taking buprenorphine. OUD, opioid use disorder; PD, pain disorder; POD, postoperative day; SL, sublingual; TD, transdermal.

Other considerations

- Maximize rational non-opioid pharmacologic options
 - Consider potential for drug interactions, sedation and overdose risk
- Employ available non-pharmacologic options including "living with pain" groups, physiotherapy, occupational therapy, psychology
- Clear discussion regarding short term nature of opioid prescribing for acute pain issues, when necessary
 - Split dosing?
- Single prescriber, limited dispensing, close follow-up

Clinical Application

Case 1: Jim

- Jim's wife leaves for 2 weeks to visit with family
- Jim takes the opportunity to indulge in a few beer
- Unfortunately, while on a ladder, Jim falls and has an acute navicular fracture for non operative management
- He is having considerable pain, what do you do?

Case 2: Kathy

- Kathy is a 33 year old female
- She has a positive family history of substance use disorder
- She herself has a long standing history of an opioid use disorder for which she is on 28mg of buprenorphine/naloxone
- She also has known Crohn's Disease which is currently in remission
- She is transferred your clinic with the following....

Pyoderma Gangrenosum



Case 2: Kathy

- Kathy presents in crisis
- She is receiving Infliximab and prednisone and is being followed by a gastroenterologist as well as a dermatologist. She has had a poor response to therapy thus far
- She is in pain. How do you proceed?

Take Home Messages

- Appreciate the individual patient's pain experience
- Manage expectations early and set realistic goals, focus on function
- Be aware of awakening the addiction circuitry and be ready to tighten treatment parameters for safety
- More research is needed:
 - Treatment of concurrent chronic pain and OUD
 - Treatment of acute/peri-operative pain in patients with OUD
- Return to first principles
 - understand the type(s) of pain that you are attempting to treat
 - prescribe medications rationally
 - Pharmacologic category
 - Dose and timing
 - utilize safer prescribing principles

References

- <u>http://www.iasp-pain.org/</u>
- College of Physicians and Surgeons of Manitoba 2015. Manitoba Methadone and Buprenorphine Maintenance: Recommended Practice.
- College of Physicians and Surgeons of Ontario 2011. Methadone Maintenance and Treatment Program: Standards and Clinical Guidelines.
- Center for Addictions and Mental Health 2011. Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guidelines.
- Greenwald MK et al. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014 Nov 1; 0: 1-11.
- National Opioid Use Guideline Group 2010. Canadian Guideline for Safe and Effective use of Opioids for Chronic Non Cancer Pain
- Crewe K.R. et al. Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 2D6 genotype and codeine therapy; 2014 update. Clinical pharmacology and therapeutics. 2014; 95:376-382.
- Rosenblum, A. et al. Prevalence and Characteristics of Chronic Pain among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities. JAMA. 2003; 289: 2370-2378.
- Katz, J. Chronic Pain, Psychopathology, and DSM-V Somatic Symptom Disorder. Can J Psych. 2015; 60 (4): 160-167.
- Noulin, DE. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag; 2014: 328-335.
- Moulin, DE. Chronic Pain in Canada Prevalence, treatment, impact and the role of opioid analgesia. Pain Res and Manag; 2002: 179-184.
- Turk D et al. Treatment of chronic non-cancer pain. Lancet. 2011; 377: 2265-35.
- Volpe DA et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regulatory Toxicology and Pharmacology 59 (2011) 385-390.
- T Anthony Anderson 1, Aurora N A Quaye, E Nalan Ward, Timothy E Wilens, Paul E Hilliard, Chad M Brummett. To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine. Anesthesiology. 2017 Jun;126(6):1180-1186.
- Akash Goel et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019 Aug;123(2):e333-e342.

Questions ???